These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33642364)

  • 1. Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system.
    Ma K; Han XX; Yang XM; Zhou SL
    Neural Regen Res; 2021 Oct; 16(10):1944-1949. PubMed ID: 33642364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier.
    Tashima T
    Antibodies (Basel); 2023 Jun; 12(3):. PubMed ID: 37489365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis-targeting chimera molecules targeting SHP2.
    Yu D; Zheng M; Liu Y; Chen L; Li H
    Future Med Chem; 2022 Apr; 14(8):587-600. PubMed ID: 35297283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
    Lospinoso Severini L; Bufalieri F; Infante P; Di Marcotullio L
    Front Cell Dev Biol; 2022; 10():854352. PubMed ID: 35242765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PROTAC technology in drug development.
    Zou Y; Ma D; Wang Y
    Cell Biochem Funct; 2019 Jan; 37(1):21-30. PubMed ID: 30604499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases.
    Hyun S; Shin D
    Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34202541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROTAC: targeted drug strategy. Principles and limitations.
    Koroleva OA; Dutikova YV; Trubnikov AV; Zenov FA; Manasova EV; Shtil AA; Kurkin AV
    Russ Chem Bull; 2022; 71(11):2310-2334. PubMed ID: 36569659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
    Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y
    Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology.
    Mukhamejanova Z; Tong Y; Xiang Q; Xu F; Pang J
    Curr Med Chem; 2021; 28(7):1304-1327. PubMed ID: 32164504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
    Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
    Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The state of the art of PROTAC technologies for drug discovery.
    Wang C; Zheng C; Wang H; Zhang L; Liu Z; Xu P
    Eur J Med Chem; 2022 May; 235():114290. PubMed ID: 35307618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
    Qi SM; Dong J; Xu ZY; Cheng XD; Zhang WD; Qin JJ
    Front Pharmacol; 2021; 12():692574. PubMed ID: 34025443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
    Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
    Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging New Concepts of Degrader Technologies.
    Ding Y; Fei Y; Lu B
    Trends Pharmacol Sci; 2020 Jul; 41(7):464-474. PubMed ID: 32416934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Protein Kinases Degradation by PROTACs.
    Yu F; Cai M; Shao L; Zhang J
    Front Chem; 2021; 9():679120. PubMed ID: 34277564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the undruggables-the power of protein degraders.
    Zhang C; Liu Y; Li G; Yang Z; Han C; Sun X; Sheng C; Ding K; Rao Y
    Sci Bull (Beijing); 2024 Jun; 69(11):1776-1797. PubMed ID: 38614856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalent Ligands for Protein Degradation in Drug Discovery.
    Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
    Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.